論文

査読有り
2017年2月

Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions

JOURNAL OF CROHNS & COLITIS
  • Kenji Suzuki
  • Junji Yokoyama
  • Yusuke Kawauchi
  • Yutaka Honda
  • Hiroki Sato
  • Yutaka Aoyagi
  • Shuji Terai
  • Kazuichi Okazaki
  • Yasuo Suzuki
  • Yukinori Sameshima
  • Tsuneo Fukushima
  • Kazuyuki Sugahara
  • Raja Atreya
  • Markus F. Neurath
  • Kenichi Watanabe
  • Hiroyuki Yoneyama
  • Hitoshi Asakura
  • 全て表示

11
2
開始ページ
221
終了ページ
228
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/ecco-jcc/jjw143
出版者・発行元
OXFORD UNIV PRESS

Background and Aims: Carbohydrate sulphotransferase 15 [CHST15] is a specific enzyme biosynthesizing chondroitin sulphate E that binds various pathogenic mediators and is known to create local fibrotic lesions. We evaluated the safety of STNM01, a synthetic double-stranded RNA oligonucleotide directed against CHST15, in Crohn's disease [CD] patients whose mucosal lesions were refractory to conventional therapy.
Methods: This was a randomized, double-blind, placebo-controlled, concentration-escalation study of STNM01 by a single-dose endoscopic submucosal injection in 18 CD patients. Cohorts of increasing concentration of STNM01 were enrolled sequentially as 2.5 nM [n = 3], 25 nM [n = 3], and 250 nM [n = 3] were applied. A cohort of placebo [n = 3] was included in each concentration. Safety was monitored for 30 days. Pharmacokinetics was monitored for 24 h. The changes from baseline in the segmental Simple Endoscopic Score for CD [SES-CD] as well as the histological fibrosis score were evaluated.
Results: STNM01 was well tolerated and showed no drug-related adverse effects in any cohort of treated patients. There were no detectable plasma concentrations of STNM01 at all measured time points in all treatment groups. Seven of nine subjects who received STNM01 showed reduction in segmental SES-CD at Day 30, when compared with those who received placebo. Histological analyses of biopsy specimens revealed that STNM01 reduced the extent of fibrosis.
Conclusion: Local application of STNM01 is safe and well tolerated in CD patients with active mucosal lesions.

リンク情報
DOI
https://doi.org/10.1093/ecco-jcc/jjw143
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/27484097
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000398096900010&DestApp=WOS_CPL
ID情報
  • DOI : 10.1093/ecco-jcc/jjw143
  • ISSN : 1873-9946
  • eISSN : 1876-4479
  • PubMed ID : 27484097
  • Web of Science ID : WOS:000398096900010

エクスポート
BibTeX RIS